🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This year's Aegean conference on Complement Therapeutics had a heartmoving surprise lurking for me! My co-organizers Lubka and Dimitris decided to dedicate the meeting to my 70th birthday, carrying out a plan that was kept in full secrecy until the kick-off of the meeting. Dear

My colleagues, collaborators, postdocs and students - THANK YOU for making this year's Aegean meeting on Complement Therapeutics an unforgettable experience for me! I was humbled to hear how I was able to positively influence so many of you - researchers and scientists from

Congratulations to the trainee travel award recipients during the #mesenchymal conference

Σας ευχαριστώ για το εξαιρετικό άρθρο που αποτυπώνει ακριβώς το πώς αντιλαμβάνομαι την σχέση μου με την έρευνα, την προσφορά στον άνθρωπο, την δύναμη των ανθρώπινων σχέσεων και την ουσία της ζωής. apopsi-press.gr/wp/2024/08/06/… via @ΑΠΟΨΗ - press

Mark your calendars! The 17th International Conference on Complement Therapeutics will convene in Sissi, Crete, Greece from 10-15 May 2025. Join a vibrant meeting that brings together leading experts and innovators from both academia and industry to share new results, challenge

Add a placeholder on your calendars and make sure you join us in Greece for the 20th Aegean Conferences on Innate Immunity! This milestone meeting will take place in Sissi, Crete from June 15-20, 2025. We will be discussing all the latest developments in various aspects of innate

Program Available: 7th International Conference on #ModelHosts in #Crete #Greece from Oct. 12-17. Registration still open! aegeanconferences.org/src/App/sessio…

Amid the dust settling from the 'explosion' of clinical approvals, here's our spotlight w/John D. Lambris, Ph.D. on the first ever therapy for patients with geographic atrophy, the #compstatin based #C3 targeted drug #Syfovre #pegcetacoplan Now out in Trends in Pharmacological Sciences sciencedirect.com/science/articl…

Deeply honoured to be included in the 2024 Highly Cited Researchers list by Clarivate/Web of Science. This recognition reflects the courageous science, hard work and unwavering dedication of so many who have shared with me this truly exciting journey of scientific discovery over

Speakers Posted: 17th Int'l Conference on #ComplementTherapeutics held in #Sissi, #Crete, #Greece from May 10-15, 2025 KALIMERA KRITI organized by John D. Lambris, Ph.D. Dimitris Mastellos Lubka Roumenina aegeanconferences.org/src/App/confer…

This year's Aegean Conference on Complement Therapeutics features a speaker roster that promises to engage the audience, fostering a productive scientific debate and cross-pollination of ideas across diverse disciplines. A great mix of leading experts and emerging talent in

Deadline Extended to Feb. 15. Abstract Submission and Trainee Award Application - 20th International Conference on #InnateImmunity in #Sissi #Crete #Greece aegeanconferences.org/src/App/confer…

The John & Rodanthi Lambris #academic sponsorships program (lambris.org) announces a call for five (5) one-year scholarships of €2,500 each (renewable upon evaluation) for the academic year 2025-2026 to university undergraduate and graduate students living in

Our News & Views article with Dimitris Mastellos discussing two recent Nature studies that report #granzymeK-mediated #complement activation in pathological contexts of CD8+ #Tcell-driven tissue #inflammation is now out in Nature Immunology nature.com/articles/s4159…

You can read our article here: rdcu.be/egmX8

Program Updated: 17th Int'l Conference on #Complement #Therapeutics held at the #KalimeraKriti Conference Center from May 10-15 in #Sissi #Crete #Greece aegeanconferences.org/src/App/sessio… Dimitris Mastellos Lubka Roumenina John D. Lambris, Ph.D.

Pleased to share our newly published paper entitled: "Clinical C3 Inhibition With AMY-101 Reveals Novel Insights Into IL-8–Driven Inflammation in COVID-19" onlinelibrary.wiley.com/doi/10.1111/im… This work, which was done a few years back, investigated the effects of AMY-101 in treating severe

Syfovre, the PEGylated version of a 2nd-generation compstatin-based C3 therapeutic (Cp05) discovered in my lab at the University of Pennsylvania (pubmed.ncbi.nlm.nih.gov/16854067/) shows a consistent safety profile over 36 months of treatment, with increasing efficacy in reducing GA lesion

Congratulations to all 17 trainee award recipients of the 20th Int’l Conference on #InnateImmunity #Sissi #Greece #Crete Fantastic Work!